Clinical pharmacokinetics of ceftriaxone
- PMID: 2686882
- DOI: 10.2165/00003088-198917040-00002
Clinical pharmacokinetics of ceftriaxone
Abstract
Ceftriaxone is a third-generation cephalosporin that exhibits saturable plasma protein binding, which influences its pharmacokinetic parameters depending on the dose. Systemic clearance and volume of distribution of total drug show dependence on both concentration and time, whereas for unbound drug these parameters remain constant. The decrease in renal or non-renal clearance with age or in the presence of disease states is often compensated by the concurrent increase in free fraction, resulting in no apparent changes in half-life and no need for dose adjustment. Because of its unusually long plasma half-life, the availability of intramuscular administration and its high intrinsic activity against many organisms, ceftriaxone has become a popular agent in once-daily therapy of infections in paediatric patients, gonococcal infections and outpatient management of pneumonia and osteomyelitis.
Similar articles
-
[Level of evidence for therapeutic drug monitoring of ceftriaxone].Therapie. 2012 Mar-Apr;67(2):145-9. doi: 10.2515/therapie/2012018. Epub 2012 Aug 2. Therapie. 2012. PMID: 22850101 Review. French.
-
Clinical use of ceftriaxone: a pharmacokinetic-pharmacodynamic perspective on the impact of minimum inhibitory concentration and serum protein binding.Clin Pharmacokinet. 2001;40(9):685-94. doi: 10.2165/00003088-200140090-00004. Clin Pharmacokinet. 2001. PMID: 11605716 Review.
-
Ceftriaxone: a third-generation cephalosporin.Drug Intell Clin Pharm. 1985 Dec;19(12):900-6. doi: 10.1177/106002808501901203. Drug Intell Clin Pharm. 1985. PMID: 3910386 Review.
-
Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model.Am J Med. 1984 Oct 19;77(4C):26-32. Am J Med. 1984. PMID: 6093514
-
Pharmacokinetics of ceftriaxone in patients undergoing continuous veno-venous hemofiltration.J Clin Pharmacol. 1996 Dec;36(12):1114-9. doi: 10.1002/j.1552-4604.1996.tb04164.x. J Clin Pharmacol. 1996. PMID: 9013367 Clinical Trial.
Cited by
-
Reversal of Borrelia burgdorferi associated dilated cardiomyopathy by antibiotic treatment?Cardiovasc Drugs Ther. 1996 Jul;10(3):351-60. doi: 10.1007/BF02627960. Cardiovasc Drugs Ther. 1996. PMID: 8877079 Clinical Trial.
-
Is Once-Daily High-Dose Ceftriaxone plus Ampicillin an Alternative for Enterococcus faecalis Infective Endocarditis in Outpatient Parenteral Antibiotic Therapy Programs?Antimicrob Agents Chemother. 2020 Dec 16;65(1):e02099-20. doi: 10.1128/AAC.02099-20. Print 2020 Dec 16. Antimicrob Agents Chemother. 2020. PMID: 33046488 Free PMC article.
-
Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases.Eur J Clin Microbiol Infect Dis. 2004 Apr;23(4):271-88. doi: 10.1007/s10096-004-1107-7. Epub 2004 Mar 10. Eur J Clin Microbiol Infect Dis. 2004. PMID: 15015030 Review.
-
Assessment of oritavancin serum protein binding across species.Antimicrob Agents Chemother. 2010 Aug;54(8):3481-3. doi: 10.1128/AAC.00271-10. Epub 2010 May 24. Antimicrob Agents Chemother. 2010. PMID: 20498314 Free PMC article.
-
Response of extensively drug resistant Salmonella Typhi to treatment with meropenem and azithromycin, in Pakistan.PLoS Negl Trop Dis. 2020 Oct 15;14(10):e0008682. doi: 10.1371/journal.pntd.0008682. eCollection 2020 Oct. PLoS Negl Trop Dis. 2020. PMID: 33057330 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources